SITE006-0178

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-09-23

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-10-25 (study day 15); relationship: not assessed

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-11-01 (study day 22); relationship: N

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-10 (study day 31); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 40); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 40); relationship: N

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 40); relationship: not assessed

Data queries

No data queries.